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Myeloid-derived suppressor cells (MDSCs) are known as key immune regulators in various human 




 MDSCs are increased in hepatocellular 
carcinoma (HCC) patients. However, the host factors that regulate the frequency and the effect on the 
prognosis of HCC patients are still unclear. We investigated these issues and clarified the 
relationships between a feature of MDSCs and host factors in HCC patients. We examined the 
frequency of MDSCs in 123 HCC patients, 30 chronic liver disease (CLD) patients without HCC and 
13 healthy controls by flow cytometric analysis. The relationships between the clinical features and 
the frequency of MDSCs were analyzed. In 33 patients who received curative radiofrequency 
ablation (RFA) therapy, we examined the impact of MDSCs on HCC recurrence. The frequency of 
MDSCs in HCC patients was significantly increased. It was correlated with tumor progression, but 
not with the degree of liver fibrosis and inflammation. In terms of serum cytokines, the 
concentrations of IL-10, IL-13 and VEGF were significantly correlated with the frequency of 
MDSCs. In HCC patients who received curative RFA therapy, the frequency of MDSCs after 
treatment showed various changes and was inversely correlated with recurrence-free survival time. 
Conclusion: The frequency of MDSCs is correlated with tumor progression and this frequency after 
RFA is inversely correlated with the prognosis of HCC patients. Patients with a high frequency of 
MDSCs after RFA should be closely followed and the inhibition of MDSCs may improve the 






































































Keywords: myeloid-derived suppressor cells, hepatocellular carcinoma, radiofrequency ablation, 
recurrence, cancer 
 
Precis: The frequency of CD14+HLA-DR-/low MDSCs in HCC patients was increased and 
correlated with tumor progression. In the patients treated by radiofrequency ablation, the frequency 




Hepatocellular carcinoma (HCC) is one of the most common malignancies and the third leading 
cause of cancer mortality globally [1, 2]. Current treatment options including surgical resection, 
radiofrequency ablation (RFA), liver transplantation, chemotherapy, transcatheter arterial 
chemoembolization (TACE) and sorafenib are reported to improve survival in HCC patients [3-7]. 
However, despite curative treatments for HCC, tumor recurrence rates remain high and the survival 
of those who have advanced HCC remains unsatisfactory [3-7]. Therefore, the development of new 
anti-tumor treatments for HCC remains an urgent and important field of research. 
To overcome the limitations of these treatments, several immunotherapies have been developed as 
attractive strategies for HCC. In several studies of HCC immunotherapy, effective induction of 
immune-mediated cells by tumor antigen-derived peptides or antigen-presenting cells showed 
anti-tumor effects, but the population of patients who exhibited such effects was very small [8-12]. 






































































immune-suppressive mechanisms [13-15]. Recently, myeloid-derived suppressor cells (MDSCs) 
have been characterized as key immune regulators in various human cancers [15-24]. They show the 
capacity to inhibit T-cell function and promote tumor development [15, 25]. Human MDSCs are a 






 and can be divided into 
granulocytic CD14
-
 and monocytic CD14
+





 MDSCs were increased in HCC patients and the cells inhibited the 
function of T cells through the induction of regulatory T cells (Tregs) [24]. Tregs represent 5% to 
10% of CD4
+




T cells [14, 
29]. It was reported that an increased frequency of circulating Tregs were associated with poor 
survival of HCC patients [30].Understanding the inhibitory mechanism of MDSCs and controlling 
their function are very important to develop more effective immunotherapy for HCC. 
In this study, we investigate the host factors that are associated with the frequency of MDSCs in 
HCC patients and the effect of MDSCs on the prognosis of patients, and clarify the relationships 







































































Materials and methods 
 
Patients and healthy controls  
 
Blood samples were obtained from a total of 123 HCC patients, 26 chronic liver disease (CLD) 
patients without HCC and 13 healthy controls. The diagnosis of HCC was histologically confirmed 
in 68 patients. For the remaining 55 patients, diagnosis was made by dynamic CT or MRI. Patient 
characteristics and disease classification are shown in Suppl. table 1. All CLD patients without HCC 
underwent percutaneous liver biopsy to evaluate the disease severity according to the Metavir 
scoring system. In 33 patients treated with curative percutaneous RFA, blood samples were obtained 
on the day of treatment and 2 to 4 weeks after treatment and we observed recurrence of these patients 
with periodic imaging studies. All subjects provided written informed consent to participate in this 
study in accordance with the Declaration of Helsinki. This study was approved by the regional ethics 
committee (Medical Ethics Committee of Kanazawa University). 
 
Cell isolation and flow cytometric analysis 
 
Peripheral blood mononuclear cells (PBMCs) were separated as described below; heparinized 






































































(Sigma, St. Louis, Mo.) in 50ml tubes. After centrifugation at 2000 rpm for 20 min at room 
temperature, PBMCs were harvested from the interphase, resuspended in PBS and centrifuged at 
1400 rpm for 10min and finally resuspended in complete culture medium consisting of RPMI 
(GibcoBRL, Grand Island, NY), 10% heat inactivated FCS (Gibco BRL), 100 U/ml penicillin and 
100 μg/ml streptomycin (Gibco BRL). PBMCs were resuspended in RPMI 1640 medium containing 
80% FCS and 10% dimethyl sulfoxide and cryopreserved until use. The viability of cryopreserved 
PBMCs was 60-70%. In some patients, fresh and cryopreserved PBMCs were obtained from the 
same sample. To determine the frequency and phenotype of MDSCs and Tregs, multicolor 
fluorescence-activated cell sorting analysis was carried out using the Becton Dickinson FACSAria II 
system. The following anti-human monoclonal antibodies were used: anti-CD4 (Becton Dickinson), 
anti-CD11b (Becton Dickinson), anti-CD14 (Becton Dickinson), anti-CD15 (Becton Dickinson), 
anti-CD25 (Becton Dickinson), anti-CD33 (Becton Dickinson), anti-CD127 (Becton Dickinson) and 












cells were sorted using the Becton Dickinson 
FACSAria II system. 2X10
4
 PBMCs were cultured and stimulated with 1g/mL plate-bound 






































































plates. 24 hours later, to determine the suppressive ability of MDSCs, increasing concentrations of 





H] thymidine was added and cell proliferation was measured by incorporation of 
radiolabeled thymidine for 24 hours.  
 
Cytokine and chemokine proﬁling 
 
Blood samples were collected from patients at the same time of PBMC isolation. After 
centrifugation at 3000 rpm for 10 min at 4°C, serum fractions were obtained and stored at -20°C 
until use. Serum levels of various cytokines and chemokines were measured using the Bio-Plex 
Protein Array System. Briefly, frozen serum samples were thawed at room temperature, diluted 1:4 
in sample diluents, and 50 l aliquots of diluted sample were added in duplicate to the wells of 
96-wellmicrotiter plates containing the coated beads for a validated panel of human cytokines and 
chemokines according to the manufacturer’s instructions. The following 27 cytokines and 
chemokines were targeted: IL-1, IL-1 receptor antagonist (IL-1Ra), IL-2, IL-4, IL-5,IL-6, IL-7, 
IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17,basic fibroblast growth factor (FGF), eotaxin 
(chemokine C-C motif ligand (CCL) 11), G-CSF,GM-CSF, IFN-, interferon gamma-induced protein 
(IP)-10, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1, 






































































cell-expressed and secreted(RANTES), TNF- and vascular endothelial growth factor(VEGF). Nine 
standards (ranging from 0.5 to 32,000 pg/ml) were used to generate calibration curves for each 





Data are expressed as the mean ± SD. Chi-squared test with Yates’ correction, unpaired t-test, 
Mann-Whitney’s U test and Kruskal-Wallis were used for univariate analysis of two groups that 
were classified according to the frequency of MDSCs. The probability of tumor recurrence-free 
survival was estimated using the Kaplan-Meier method. The Mantel-Cox log-rank test was used to 
compare curves between groups. The prognostic factors for tumor recurrence-free survival were 
analyzed for statistical significance by the Kaplan-Meier method (univariate) and the Cox 
proportional hazard model (multivariate). Variables with p< 0.1 were entered into multivariate 















































































We analyzed the peripheral blood of 123 patients with HCC, 26CLD patients without HCC and 13 




MDSCs. Because the PBMCs are tested 
after Ficoll, where some cells may be lost. Therefore, we examined the population of MDSCs as a 
percentage of total CD14
+
 cells by flow cytometry after cell surface labeling for expression of 




population in PBMCs of HCC patients represented 3.2% 
to 56.8% of the CD14
+




 MDSCs / CD14
+
cells in 





 MDSCs / CD14
+
cells using cryopreserved PBMCs. 









(control) cells were added at different ratios to autologous anti-CD3/CD28-stimulated PBMCs and 






 MDSCs of HCC patients 





 (control) cells could not suppress the autologous PBMC proliferation. 
As shown in Figure 1D, the frequency of MDSCs was significantly higher in HCC patients 
(19.0%) than in healthy donors (9.4%) (p< 0.01). Overall frequencies of CD14
+
 cells did not differ 
significantly between the groups (Figure 1E). Individual frequencies of MDSCs of all the patients 
and healthy donors are represented as scatter plots (Figure 2A). The frequency of MDSCs was 






































































p< 0.01) and was significantly higher in HCC patients than CLD patients without HCC and healthy 
donors. Interestingly, there was no difference between CLD patients without HCC and healthy 
donors. Moreover, these numbers did not change depending on the degree of fibrosis or 
inflammatory activity of the liver (Figures 2B and 2C).  
In previous reports, granulocytic MDSCs were defined in combination with several surface 
markers including CD14, CD15, CD11b, CD33, CD66b and HLA-DR in several cancers. Therefore, 








 cells in 37 HCC patients and 11 healthy 









 cells in HCC patients was higher than that in healthy donors. (2.84% vs. 
2.06%, p = 0.073) (Suppl. figure 1B). The frequency was correlated with the stage of HCC (stage III 
and IV: 3.69% (n=13) vs. stage I and II: 2.39% (n=24), p= 0.022) (Suppl. figure 1C). 
 
Relationship between the frequency of Tregs and MDSCs  
 
It is well known that the frequency of circulating Tregs is increased and correlated with disease 






 Tregs was significantly 
increased in HCC patients (Suppl. figure 2A) and associated with tumor progression (Suppl. figure 
2B). However, there was not a strong correlation between the frequency of MDSCs and Tregs in our 







































































Identification of host factors related to the frequency of MDSCs in HCC patients 
 
We divided the HCC patients into two groups using the threshold of an MDSC ratio of 22%. This 
threshold is the average + 2SD of the MDSC ratio in non-HCC patients. In the group with high 
frequency, the tumor factors including size, multiplicity and stage were significantly worse (tumor 
size, 28.3mm vs. 24.4mm; tumor multiplicity (multiple/solitary), 27/12 vs. 42/42; TNM stage (I and 
II vs. III and IV), 17/22 vs. 60/24, p< 0.05) (Table1). In addition, hepatic reserve was also worse in 
the group with high frequency (Child-Pugh classification (A/B/C), 20/17/2 vs. 64/16/4, p< 0.05). In 
addition, overall survival was significantly shortened in the group with high frequency (hazard ratio 
2.67, p= 0.008) (Suppl. figure 3A), and recurrence free survival was also significantly shortened 
(hazard ratio 1.94, p= 0.010) (Suppl. figure 3B). 
 
Relationship between serum cytokine levels and the frequency of MDSCs 
 
In previous studies, the balance of circulating cytokines was thought to promote accumulation and 
activation of MDSCs [18, 36-39]. Therefore, we examined the relationship between serum cytokine 
levels and the frequency of MDSCs in HCC patients. In 54 HCC patients, serum levels of cytokines 






































































IL-10, IL-13 and VEGF were significantly increased in the group with a high frequency of MDSCs 
(Table 2). In addition, there was a positive correlation between these cytokine levels in serum and the 
frequency of MDSCs. We also examined the relationship between serum cytokine levels and the 
frequency of Tregs. We divided the HCC patients into two groups using the threshold of 7%, which 
is the average + 2SD of the % of Tregs among CD4
+
 cells in non-HCC patients. Serum concentration 
of IL-10 was significantly increased in the group with a high frequency of Tregs (Suppl. table 2). 
 
Kinetics of MDSCs before and after curative RFA therapy 
 
We examined the frequency of MDSCs before and after curative RFA therapy in 33 patients. For 
this analysis, blood samples were obtained on the day of treatment (before) and 2 to 4 weeks after 
treatment (after). The frequency of MDSCs was significantly decreased after RFA therapy (18.0% to 
15.5%, p< 0.05) (Figure 3A). However, in several patients, the frequency of MDSCs remained at a 
high level compared with that in non-HCC patients. The clinical parameters before RFA were not 
statistically different between the patients with and without a high frequency of MDSCs after RFA 
(Suppl. table 3).  
Next, we followed up these patients for recurrence and analyzed the risk factors. If a high 
frequency of MDSC was observed after curative RFA therapy, the recurrence-free survival was 






































































affect the recurrence. In univariate analysis for recurrence, post-treatment MDSC ratio ≥22% (p= 
0.023) and tumor multiplicity (p= 0.010) were significantly associated with HCC recurrence (Table 
3). In multivariable analysis for recurrence, considering the variables in the univariate analysis with 
p< 0.1, only post-treatment MDSC ratio ≥22% (HR 3.906, p= 0.014) was extracted as a significant 








































































MDSCs are expanded in pathological conditions such as malignancy, infection or trauma and 
consist of a heterogeneous population of immature myeloid cells [15, 25]. In pathological conditions, 
immature myeloid cells are blocked to differentiate into mature macrophages, dendritic cells or 
granulocytes; as a result, MDSCs are accumulated [15, 25]. MDSCs strongly inhibit anti-tumor 





MDSCs have been reported in various malignancies, including melanoma, 
multiple myeloma, prostate cancer and bladder cancer [18, 20, 22, 35]. In the most recent study, 




MDSCs were significantly increased in HCC patients 






 Treg [24]. 
In the present study, in addition to an increase in the number of MDSCs in HCC patients, we 
observed that the frequency was correlated with the progression of HCC. Consistent with our results, 




 MDSCs was correlated with 
tumor progression in patients with other cancers, such as melanoma, prostate cancer and bladder 
cancer [22, 35, 36]. However, the mechanisms behind the increase of MDSCs in advanced cancer 
patients are still unclear. As is well known, there is a close relationship between 
hepatocarcinogenesis and histological status of underlying liver [37, 38]. Therefore, the advance of 











































































 MDSCs and underlying liver status in our study. From our 
observations, increase of MDSCs was only correlated with tumor progression, but not with hepatic 




MDSCs was mostly derived from the tumor environment itself, but not from inflammation or fibrosis 





MDSCs is observed in most patients with curative treatment in this 
study supports this hypothesis. On the other hand, Tregs were also increased in HCC patients and 
associated with the progression of HCC. Though it was reported that MDSCs suppressed T cell 
function through the induction of Tregs, there was not a strong correlation between the frequencies of 
these two immunosuppressive cells.  
Regarding the mechanism of MDSC expansion, we also analyzed the relationship between the 
serum cytokine levels and the frequency of MDSCs. We observed that the serum concentrations of 
IL-10, IL-13 and VEGF were significantly increased in the group with high frequency of MDSCs 
and there was a positive correlation between these cytokine levels and the frequency of MDSCs. 
Moreover, although there was no significant difference, the serum concentrations of IL-1ra, IL-2, 
IL-6, IL-12(p70) and G-CSF tended to be increased in the group with high frequency of MDSCs. In 
accordance with our results, various cytokines, including IL-6, IL-10, IL-13, G-CSF and VEGF, that 






































































pathways have been reported to be associated with the frequency of MDSCs [39]. In particular, the 
cytokines involved in the JAK2-STAT3 signaling pathway are considered to be the main regulators 
of the expansion of MDSCs, which leads to stimulation of myelopoiesis and inhibition of 
myeloid-cell differentiation [40-42].  
Another important finding of our study is that the frequency of MDSCs showed various changes 
after curative RFA and this frequency is an independent risk factor of HCC recurrence. In most of the 
patients, the frequency of MDSCs decreased after RFA. A similar phenomenon has also been 
reported in other cancer treatments [19, 21, 36]. Liu et al. reported that MDSCs were decreased in 
non-small cell lung cancer patients who had clinical benefit from chemotherapy or who received 
curative surgery [21]. These results suggest that a decrease of the frequency of MDSCs is due to 
tumor eradication. 
It is well known that tumor factors including multiplicity, tumor diameter, serum levels of tumor 
marker and hepatic reserve are risk factors of HCC recurrence after RFA [43, 44], but it has not been 
reported that the frequency of circulating MDSCs is also a risk factor. From our findings, there was a 
clear inverse correlation between the frequency of MDSCs after RFA and recurrence-free survival. 
Consistent with our results, in the patients with pancreatic, esophageal and gastric cancer, Gabitass et 
al. reported that an increase of MDSCs was associated with an increased risk of death and that the 
frequency of MDSCs was an independent prognostic factor for patient survival[23]. Taken together 






































































factors of patients after cancer treatments. 
As we showed, the frequency of MDSCs is primarily correlated with tumor progression. However, 
between the patients with high and low frequency of MDSCs after RFA, there was no significant 
difference in hepatic reserve and tumor factors before treatment. Although an incomplete HCC 
eradication at a microscopic level may allow a high frequency of MDSCs after RFA, there may be 
other mechanisms such as subsequently tumor-specific immune responses after RFA. In addition, 
there is a limitation of the present study because we used cryopreserved PBMCs for phenotypic 
analysis of MDSCs. Further studies using fresh PBMCs are needed for precise phenotypic analysis 
of MDSCs and elucidation of the mechanism to regulate the frequency of MDSCs after HCC 
treatment. 
In conclusion, the frequency of MDSCs in HCC patients is correlated with tumor progression and 
the frequency after RFA is inversely correlated with the prognosis of HCC patients. HCC patients 
who show a high frequency of MDSCs after RFA should be closely followed and the inhibition or 
elimination of MDSCs after HCC treatments may improve the prognosis of HCC patients.  
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for local recurrence of small hepatocellular carcinoma tumors after a single session, single 













































































































MDSCs. PBMCs from patients and 
healthy donors were labeled with anti-CD14 and HLA-DR. Three staining examples of HCC patients 







 cells in cryopreserve PBMC correlated with that in fresh PBMC 
(r2=0.52). (C) Proliferation of PBMCs stimulated by anti-CD3/28 in the presence or absence of 






 MDSCs significantly decreased 
autologous PBMC proliferation (n=4; *, p<0.05). (D) The frequency of MDSCs was significantly 
higher in HCC patients than healthy donors (*, p<0.01). (E) Overall frequencies of CD14
+
 cells did 
not differ significantly. 






 cells) in patients 
and healthy donors. The frequency of MDSCs was significantly increased in HCC patients compared 
with that in non-HCC controls. Moreover, the frequency of MDSCs was correlated with tumor 
progression (stage III and IV: 22.3% (n=46) vs. stage I and II: 17.0% (n=77); *, p<0.05). In 
non-HCC controls, there was no significant difference in the frequency of MDSCs. (B), (C) In 
non-HCC patients, the frequency of MDSCs did not change depending on the degree of fibrosis or 
inflammatory activity of the liver according to the Metavir scoring system. 
Figure 3:  (A) In 33 HCC patients who received curative RFA therapy, the frequency of MDSCs 






































































increased after treatment (dotted lines) (*, p< 0.05). (B) Kaplan-Meier curve for recurrence-free 


































































Table 1. Clinical findings and MDSCs 
Clinical characteristics 
  MDSC ratio ≥22  
 (n=39) 
 MDSC ratio < 22   
(n=84) 
 p value 
Age (yr) 68.5 70.1  0.646 
Sex (M/F) 29/10 54/30  0.267 
AST (IU/l) 62.0 61.5  0.543 
ALT (IU/l) 47.1 53.9  0.759 
LDH (IU/l) 225 218  0.832 
γGTP (IU/l) 78.0 76.0  0.252 
Platelet (10⁴/μl) 10.9 10.6  0.884 
Prothrombin time (%) 75.2 82.3  0.045 
Serum albmin (g/dl) 3.53 3.68  0.120 
Total Bilirubin (mg/dl) 1.21 0.94  0.286 
WBC (/μl) 3910 3610  0.235 
Neutrophil (%) 63.2 59.4  0.093 
Lymphocyte (%) 26.1 29.5  0.047 
Total Cholesterol (mg/dl) 151 149  0.926 
HbA1c (%) 5.27 5.43  0.197 
Type IV collagen 7S (ng/ml) 8.2 7.3  0.086 
DCP (mAU/ml) 5157 432  0.561 
AFP (ng/ml) 1301 934  0.240 
Tumor Size (mm) 28.3 24.4  0.014 
Tumor Multiplicity 
(multiple/solitary) 
27/12 42/42  0.046 
TNM Stage (I plus II/III plus IV) 17/22 60/24  0.003 
Child-Pugh (A/B/C) 20/17/2 64/16/4  0.015 
Etiology (HCV/HBV/others) 21/11/7 61/11/12  0.081 
CD4+ CD25+ CD127-/low Tregs /  
CD4+ cells (%) 
7.04 6.70  0.281 
Abbreviations: AST, aspirate aminotransferase; ALT, alanine aminotransferase; LDH, lactic dehydrogenase; γGTP, gamma glutamyltransferase; WBC, 
white blood cell; Hb, hemoglobin; DCP, des-gamma-prothrombin; AFP, Alpha-fetoprotein; HCV, hepatitis C virus; HBV, hepatitis B virus; Tregs, 
regulatory T cells 
Chi-squared test with Yates’ correction, unpaired t-test, Mann-Whitney’s U test and Kruskal-Wallis test were used for univariate analysis of two groups 
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Table 2. Serum cytokines and MDSCs 
Cytokine Healthy donor  
(mean) 
(n=13) 
MDSC ratio ≥22 
(mean)   
(n=21) 
Range MDSC ratio < 22  
(mean) 
(n=31) 
Range p value 
IL-1ra 34.2 97.0 (21.5-600) 40.3 (3.4-151) 0.057 
IL-2 10.5 38.1 (4.3-54.3) 11.3 (0.9-49.7) 0.055 
IL-4 2.6 5.75 (1.47-11.9) 5.03 (0.71-10.9) 0.159 
IL-6 9.9 21.5 (1.2-130) 10.1 (0.2-97.2) 0.065 
IL-8 24.5 64.7 (10.9-291) 35.1 (6.2-142) 0.156 
IL-10 2.76 6.01 (0.8-11.5) 2.81 (0.1-12.0) 0.003 
IL-12(p70) 14.6 33.3 (0.6-140) 17.6 (1.4-57) 0.058 
IL-13 7.6 13.1 (1.2-33.6) 8.2 (2.7-22.9) 0.015 
IL-17 15.7 23.5 (4.6-70) 20.8 (2.1-119) 0.115 
Eotaxin 104 141 (51.9-493) 124 (26.3-331) 0.675 
G-CSF 7.9 13.2 (2.7-41.3) 8.7 (0.5-17.9) 0.050 
IFN-γ 52.6 95.4 (23.1-417) 69.9 (2.5-238) 0.136 
MCP-1 20.2 26.8 (8.4-114) 23.8 (3.5-77) 0.744 
MIP-1b 97.6 120 (58.3-490) 108 (39.7-263) 0.508 
PDGF 4012 4375 (1312-10136) 4013 (831-13557) 0.484 
RANTES 2978 2890 (1040-4826) 3184 (599-6165) 0.186 
TNF-α 10.5 34.9 (0.1-175) 27.6 (2.9-105) 0.756 
VEGF 34.6 101.7 (22.5-371) 59.5 (9.3-183) 0.045 
Abbreviations: IL, interleukin; G-CSF, granulocytic colony stimulating factor; IFN, interferon; MCP, monocyte chemoattractant protein; MIP, 
macrophage inflammatory protein; PDGF, platelet-derived growth factor; RANTES, regulated upon activation, normal T cell-expressed and secreted; 
TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor 








Table 3. Cox proportional-hazards regression for recurrence 
Variant Univariate HR (95% CI) p value Multivariable HR (95% CI) p value 
Sex: female 0.763 (0.446-1.308) 0.326   
Age: ≥70 yr 1.111 (0.671-1.840) 0.683   
Pre MDSC ratio: ≥22% 1.210 (0.698-2.096) 0.497   
Pre neutrophil 0.990 (0.969-1.012) 0.385   
Pre lymphocyte 1.014 (0.987-1.043) 0.311   
Pre neutrophil/lymphocyte 0.978 (0.787-1.216) 0.844   
Pre ALT 1.001 (0993-1.008) 0.882   
Pre serum albumin: < 3.5 mg/dl 1.143 (0.665-1.982) 0.647   
Pre prothrombin time: < 70% 1.662 (0.961-2.903) 0.073 1.881 (0.522-6.777) 0.101 
Post MDSC ratio: ≥22%  2.795 (1.150-6.792) 0.023 3.906 (1.313-11.616) 0.014 
Post neutrophil 1.005 (0.975-1.035) 0.762   
Post lymphocyte 0.993 (0.960-1.027) 0.678   
Post neutrophil/lymphocyte 1.003 (0.810-1.242) 0.980   
Post ALT 0.995 (0.981-1.010) 0.501   
type IV collagen 7S  1.122 (0.992-1.268) 0.067 1.192 (0.907-1.566) 0.207 
AFP: ≥100 ng/ml 1.357 (0.743-2.480) 0.321   
Tumor size: ≥20 mm 1.29 (0.78-2.12) 0.328   
Tumor Multiplicity: multiple 2.00 (1.18-3.40) 0.010 1.851 (0.721-4.753) 0.201 
Abbreviations: HR, hazard ratio; CI, confidence interval; ALT, alanine aminotransferase; AFP, Alpha-fetoprotein 
Figure
Click here to download high resolution image
Figure2
Click here to download high resolution image
Figure3
Click here to download high resolution image
1 
 

















HCC patients 123 83/40 52 ± 36 82/22/19 1051 ± 4391 84/33/6 69/54 69/54 32/45/35/11 
CLD patients 26 14/12 46 ± 27 22/4/0 11 ± 7 26/0/0 ND ND ND 
Healthy donors 13 8/5 17 ± 5 ND ND ND ND ND ND 
Abbreviations: ALT, alanine aminotransferase; HCV, hepatitis C virus; HBV hepatitis B virus; AFP, Alpha-fetoprotein; HCC, hepatocellular carcinoma; CLD, chronic liver disease;  
SD, standard deviation 
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Cytokine Healthy donor 
(mean) 
(n=13) 






Range p value 
IL-1ra 34.2 54.2 (11.0-430) 79.7 (5.9-600) 0.383 
IL-2 10.5 26.0 (2.1-54.3) 16.0 (0.9-50.6) 0.167 
IL-4 2.6 6.17 (1.47-11.9) 4.54 (0.71-10.9) 0.128 
IL-6 9.9 14.6 (0.2-97.2) 15.1 (1.6-130) 0.872 
IL-8 24.5 49.5 (6.2-291) 40.1 (10.9-256) 0.563 
IL-10 2.76 4.99 (0.6-12.1) 2.97 (0.1-10.4) 0.030 
IL-12(p70) 14.6 25.8 (0.6-140) 23.2 (2.8-78) 0.715 
IL-13 7.6 11.6 (2.7-33.6) 8.8 (1.2-22.9) 0.167 
IL-17 15.7 20.1 (4.2-70) 25.4 (2.1-119) 0.340 
Eotaxin 104 132 (59.0-493) 119 (26.3-245) 0.906 
G-CSF 7.9 11.2 (2.7-41.3) 10.1 (0.5-33.7) 0.424 
IFN-γ 52.6 85.9 (23.1-417) 78.6 (2.5-343) 0.319 
MCP-1 20.2 27.2 (3.5-114) 21.9 (8.4-71) 0.375 
MIP-1b 97.6 123 (56.6-490) 103 (39.7-229) 0.696 
PDGF 4012 4179 (1271-10136) 4305 (831-13557) 0.815 
RANTES 2978 3041 (1040-4714) 3097 (599-6165) 0.598 
TNF-α 10.5 29.1 (0.1-175) 32.7 (2.9-155) 0.747 
VEGF 34.6 83.4 (24.5-371) 71.9 (9.3-224) 0.538 
Abbreviations: IL, interleukin; G-CSF, granulocytic colony stimulating factor; IFN, interferon; MCP, monocyte chemoattractant protein; MIP, 
macrophage inflammatory protein; PDGF, platelet-derived growth factor; RANTES, regulated upon activation, normal T cell-expressed and secreted; 
TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor 















Supplemental table 3. The clinical parameters before RFA  
Clinical characteristics 
  MDSC ratio ≥22  
 (n=8) 
 MDSC ratio < 22   
(n=25) 
 p value 
Pre MDSC ratio (%) 28.7 14.8  0.004 
Post MDSC ratio (%) 30.2 10.8  <0.001 
Sex (M/F) 6/2 13/12  0.252 
Prothrombin time (%) 82.8 79.9  0.663 
Serum albmin (g/dl) 3.70 3.67  0.794 
Total bilirubin  0.83 1.03  0.408 
Platelet (10⁴/μl) 8.6 9.5  0.473 
Type IV collagen 7S (ng/ml) 7.5 7.6  0.924 
AFP (ng/ml) 146 41.7  0.214 
Pre neutrophil/lymphocyte 1.98 2.19  0.486 
Post neutrophil/lymphocyte 2.70 2.16  0.097 
Pre ALT (IU/l) 45.0 55.3  0.421 
Post ALT (IU/l) 42.6 52.2  0.584 
Child-Pugh (A/B/C) 7/1/0 20/5/0  0.632 
Tumor Size (mm) 21.8 18.2  0.313 
Tumor Multiplicity 
(multiple/solitary) 
6/2 13/12  0.252 
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 CD15+ CD14- CD11b+ CD33+ cells / PBMCs B 
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HCC stage I 
  (n=31) 
stage  II, III 
   (n=78) 
stage IV 
   (n=8) 
 Tregs / CD4+ cells B C  Tregs / CD4+ cells A CD4+ CD25+ CD127 -/low Tregs  
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Suppl. fig. 2 
  MDSC ratio  22 ≤   (n=32) 




























  hazard ratio  1.94 





















  MDSC ratio  22 ≤   (n=39) 
  MDSC ratio  < 22   (n=84) 
  hazard ratio  2.67 
  p=0.008 
A B Overall survival Recurrence free survival 






















 cells in PBMCs was higher in HCC patients than healthy donors (2.84% 








 cellswas correlated with 
tumor progression (stage III and IV: 3.69% (n=13) vs. stage I and II: 2.39% (n=24), p= 0.022). 













 Tregs was significantly increased in HCC patients than healthy donors (*, p<0.01). 
(C) The frequency of Tregs was correlated with tumor progression. (D) There was only a weak 











Tregs (r=0.24).  
Suppl. figure 3:  (A) Kaplan-Meier curve for overall survival in our cohort.  (B) Kaplan-Meier 
curve for recurrence free survival in our cohort. 
 
